FBRX
Forte Biosciences, Inc.
Key Financials
Operating Income
$-70657000
↓ 93.0%
Revenue
$36000
↓ 99.8%
Net Income
$-69375000
↓ 95.5%
Total Assets
$82.8M
↑ 34.5%
Total Liabilities
$21.8M
↑ 139.9%
Shareholders' Equity
$61.0M
↑ 16.2%
EPS (Diluted)
$-4.71
↑ 61.3%
Cash & Equivalents
$77.0M
↑ 246.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 15-12G | 9/8/2026 | View on SEC |
| 15-12G | 9/8/2026 | View on SEC |
| 15-12G | 9/8/2026 | View on SEC |
| SCHEDULE 13G/A | 9/8/2026 | View on SEC |
| EFFECT | 9/1/2026 | View on SEC |
| EFFECT | 9/1/2026 | View on SEC |
| EFFECT | 9/1/2026 | View on SEC |
| EFFECT | 9/1/2026 | View on SEC |
| EFFECT | 9/1/2026 | View on SEC |
| EFFECT | 9/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | FBRX |
| Company Name | Forte Biosciences, Inc. |
| CIK | 1419041 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (310) 618-6994 |